Myeloma: Update on supportive care strategies

被引：0

作者：

Jesús F. San Miguel

Ramón García-Sanz

机构：

[1] Department of Hematology, University Hospital of Salamanca, Paso de San Vicente 52-182, Salamanca

来源：

Current Treatment Options in Oncology | 2003年 / 4卷 / 3期

关键词：

Hypercalcemia; Ibandronate; Multiple Myeloma; Pamidronate; Zoledronic Acid;

D O I：

10.1007/s11864-003-0026-7

中图分类号：

学科分类号：

摘要：

Despite substantial innovations in the treatment of multiple myeloma (MM), it remains an incurable disease. In addition, it is debatable whether the progress in survival is attributable simply to the therapy used to destroy the tumor clone or if it is also because of therapy designed to ameliorate disease complications. Supportive therapy has evolved greatly alongside general supportive measures used in hematologic malignancies (such as new antibiotics, antifungal agents, and growth factors) in addition to better indications in complementary treatments such as radiotherapy, dialysis, and surgery. However, in MM, several specific adjuvant therapies have also been introduced (eg, bisphosphonates and erythroid-stimulating factors), which have conferred a key role to supportive therapy in the general treatment of patients with MM. © 2003, Current Science Inc.

引用

页码：247 / 258

页数：11

共 51 条

[1]

San M.J.F., Blade J., Garcia-Sanz R., Treatment of multiple myeloma, Haematologica, 84, pp. 36-58, (1999)

[2]

Supportive therapy for complications in multiple myeloma, . in Education Sessions of the Second Meeting of the European Haematology Association, 1996, pp. 12-16, (1996)

[3]

San M.J.F., Garcia-Sanz R., Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin’s lymphoma, Med Oncol, 15, pp. S29-S34, (1998)

[4]

Silvestris F., Cafforio P., Tucci M., Dammacco F., Negative regulation of erythroblast maturation by Fas-L+/ TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma, Blood, 99, pp. 1305-1313, (2002)

[5]

Garton J.P., Gertz M.A., Witzig T.E., Et al., Epoietin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled double blind trial, Arch Intern Med, 155, pp. 2069-2074, (1995)

[6]

Cazzola M., Messinger D., Battistel V., Et al., Recombinant human erythropoietin in the anemia associated with multiple myeloma and non-Hodgkin’s lymphoma: dose finding and identification of predictors of response, Blood, 86, pp. 4446-4453, (1995)

[7]

Osterborg A., Boogaerts M.A., Cimino R., Et al., Recombinant human erythropoietin in transfusiondependent patients with multiple myeloma and non-Hodgkin’s lymphoma: a randomized multicenter study. The European Study Group of Erythropoietin (Epoietin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma, Blood, 87, pp. 2675-2682, (1996)

[8]

Littlewood T.J., Bajetta E., Nortier J.W., Et al., Effects of epoietin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial, J Clin Oncol, 19, pp. 2865-2874, (2001)

[9]

Dammacco F., Castoldi G., Rodjer S., Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma, Br J Haematol, 113, pp. 172-179, (2001)

[10]

Osterborg A., Brandberg Y., Molostova V., Et al., Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies, J Clin Oncol, 20, pp. 2486-2494, (2002)

← 1 2 3 4 5 6 →